Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study is a one-arm, open, phase II clinical study, and the study subjects are locally
advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered
the trial period after signing informed consentTo evaluate trastuzumab combined with
pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete
response rate (pCR) for adenocarcinoma.